Company profile ADPT
Adaptive Biotechnologies Corp
we are a commercial-stage, biotechnology organization located in the hot biotech locations of seattle, washington and south san francisco, ca. our world class scientists have invented a patent-pending technology that combines advances in high-throughput sequencing with state-of-the-art computer infrastructure to provide an in-depth analysis of the t- and b-cell repertoire, a sp...ecific and important part of the immune system. this information is driving the r&d community to support the fights against cancer, auto-immune disease, and much, much more. we're often asked to describe our company culture. it is very easy ... we're a hard working group of top-notch individuals who are passionate about wanting to make a difference in the world. we know our employees are our most valuable asset, and every employee’s contribution is appreciated. open communication and collaboration are always encouraged in every interaction throughout the organization. we have high expectations of ourselves, and
Show More
After 39 days of this quarter the interest is at 120.0. Based on that we can calculate that during remaining 52 days it will total up to 280.0. Adaptive Biotechnologies news expected interest is significantly higher compared to previous quarter (+263.6%) and same quarter last year (+1373.7%).
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 58 | 68 17.2% QoQ | 35 -48.5% QoQ | 141 302.9% QoQ |
| 2020 | 8 -86.2% YoY -94.3% QoQ | 20 -70.6% YoY 150.0% QoQ | 17 -51.4% YoY -15.0% QoQ | 48 -66.0% YoY 182.4% QoQ |
| 2021 | 31 287.5% YoY -35.4% QoQ | 46 130.0% YoY 48.4% QoQ | 9 -47.1% YoY -80.4% QoQ | 40 -16.7% YoY 344.4% QoQ |
| 2022 | 59 90.3% YoY 47.5% QoQ | 72 56.5% YoY 22.0% QoQ | 33 266.7% YoY -54.2% QoQ | 44 10.0% YoY 33.3% QoQ |
| 2023 | 19 -67.8% YoY -56.8% QoQ | 30 -58.3% YoY 57.9% QoQ | 32 -3.0% YoY 6.7% QoQ | 77 75.0% YoY 140.6% QoQ |
| 2024 | 120 531.6% YoY 55.8% QoQ | - | - | - |
this symbol represents interest this quarter up to now and updates daily. For expected interest by the end of the quarter based on current trend see "Quarter analysis" above the table.
Interest value is multiplied to fit the chart properly. Correlation level is represented by Pearson correlation coefficient. Value closer to 1 represents higher level of correlation. Value closer to -1 represents inverted relationship. Value closer to 0 represents no relationship.
The average 5 years interest of Adaptive Biotechnologies news was 3.86 per week. The last year interest of Adaptive Biotechnologies news compared to the last 5 years has changed by 29.02%. This is something to be checked. The last year interest is comparable to 5 years ago. It has changed only by -14.29%.
Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
After 39 days of this quarter the interest is at 119.0. Based on that we can calculate that during remaining 52 days it will total up to 278.0. Adaptive Biotechnologies -stock -company expected interest is significantly higher compared to previous quarter (+219.5%) and same quarter last year (+334.4%).
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 34 | 256 652.9% QoQ | 167 -34.8% QoQ | 131 -21.6% QoQ |
| 2020 | 148 335.3% YoY 13.0% QoQ | 177 -30.9% YoY 19.6% QoQ | 119 -28.7% YoY -32.8% QoQ | 100 -23.7% YoY -16.0% QoQ |
| 2021 | 156 5.4% YoY 56.0% QoQ | 121 -31.6% YoY -22.4% QoQ | 113 -5.0% YoY -6.6% QoQ | 106 6.0% YoY -6.2% QoQ |
| 2022 | 148 -5.1% YoY 39.6% QoQ | 114 -5.8% YoY -23.0% QoQ | 123 8.8% YoY 7.9% QoQ | 130 22.6% YoY 5.7% QoQ |
| 2023 | 64 -56.8% YoY -50.8% QoQ | 80 -29.8% YoY 25.0% QoQ | 83 -32.5% YoY 3.8% QoQ | 87 -33.1% YoY 4.8% QoQ |
| 2024 | 119 85.9% YoY 36.8% QoQ | - | - | - |
this symbol represents interest this quarter up to now and updates daily. For expected interest by the end of the quarter based on current trend see "Quarter analysis" above the table.
Interest value is multiplied to fit the chart properly. Correlation level is represented by Pearson correlation coefficient. Value closer to 1 represents higher level of correlation. Value closer to -1 represents inverted relationship. Value closer to 0 represents no relationship.
The average 5 years interest of Adaptive Biotechnologies -stock -company was 9.87 per week. The last year interest of Adaptive Biotechnologies -stock -company compared to the last 5 years has changed by -21.88%. This is something to be checked. The last year interest is quite lower compared to 5 years ago. It has decreased by -38.22%.
Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Useful links and data for ADPT
Company name: Adaptive Biotechnologies Corp
Sector: Manufacturing
Company's websiteHyperchartsYahoo FinanceMarketWatchStockTwitsSEC FilingsSwaggyStocksLatest articles
2026-05-12T16:22:15Z
Analyst Upgrades
Morgan Stanley Maintains Equal-Weight on Adaptive Biotechnologies, Lowers Price Target to $182026-05-06T20:16:47Z
Analyst Upgrades
JP Morgan Maintains Overweight on Adaptive Biotechnologies, Lowers Price Target to $192026-05-06T18:30:48Z
Analyst Upgrades
TD Cowen Maintains Buy on Adaptive Biotechnologies, Raises Price Target to $212026-05-06T14:49:45Z
Analyst Upgrades
Guggenheim Reiterates Buy on Adaptive Biotechnologies, Maintains $21 Price Target2026-05-06T11:58:15Z
Analyst Upgrades
BTIG Reiterates Buy on Adaptive Biotechnologies, Maintains $22 Price Target2026-05-05T20:05:00Z
GlobeNewswire
Adaptive Biotechnologies Reports First Quarter 2026 Financial Results2026-04-24T16:32:11-04:00
SEC
ARS Form - Annual Report to Security Holders - Adaptive Biotechnologies Corp (0001478320) (Filer)2026-04-24T16:31:02-04:00
SEC
DEFA14A Form - Additional definitive proxy soliciting materials and Rule 14(a)(12) material - Adaptive Biotechnologies Corp (0001478320) (Filer)2026-04-24T16:30:23-04:00
SEC
DEF 14A Form - Other definitive proxy statements - Adaptive Biotechnologies Corp (0001478320) (Filer)2026-04-15T20:05:00Z
GlobeNewswire
Adaptive Biotechnologies to Report First Quarter 2026 Financial Results on May 5, 20262026-02-06T20:37:52Z
Analyst Upgrades
JP Morgan Maintains Overweight on Adaptive Biotechnologies, Raises Price Target to $212026-02-06T11:36:56Z
Analyst Upgrades
BTIG Maintains Buy on Adaptive Biotechnologies, Raises Price Target to $222026-02-05T21:05:00Z
GlobeNewswire
Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2025 Financial Results2026-01-27T21:05:00Z
GlobeNewswire
Adaptive Biotechnologies to Participate in Upcoming Investor Conferences2026-01-26T16:24:54Z
Analyst Upgrades
Guggenheim Maintains Buy on Adaptive Biotechnologies, Raises Price Target to $21